- Home
- COCH vs OCX Comparison
COCH vs OCX Comparison
Compare COCH & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- OCX
- Stock Information
- Founded
- COCH 1995
- OCX 2009
- Country
- COCH United States
- OCX United States
- Employees
- COCH N/A
- OCX N/A
- Industry
- COCH Blank Checks
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- COCH Finance
- OCX Health Care
- Exchange
- COCH Nasdaq
- OCX Nasdaq
- Market Cap
- COCH 29.8M
- OCX 35.1M
- IPO Year
- COCH N/A
- OCX N/A
- Fundamental
- Price
- COCH $1.41
- OCX $2.08
- Analyst Decision
- COCH Strong Buy
- OCX Buy
- Analyst Count
- COCH 3
- OCX 3
- Target Price
- COCH $8.00
- OCX $4.42
- AVG Volume (30 Days)
- COCH 54.8K
- OCX 69.1K
- Earning Date
- COCH 11-14-2024
- OCX 11-12-2024
- Dividend Yield
- COCH N/A
- OCX N/A
- EPS Growth
- COCH N/A
- OCX N/A
- EPS
- COCH N/A
- OCX N/A
- Revenue
- COCH $278,000.00
- OCX $709,000.00
- Revenue This Year
- COCH N/A
- OCX N/A
- Revenue Next Year
- COCH $19.76
- OCX $106.34
- P/E Ratio
- COCH N/A
- OCX N/A
- Revenue Growth
- COCH 15.35
- OCX N/A
- 52 Week Low
- COCH $1.08
- OCX $1.97
- 52 Week High
- COCH $11.46
- OCX $3.48
- Technical
- Relative Strength Index (RSI)
- COCH 38.92
- OCX 37.86
- Support Level
- COCH $1.21
- OCX $2.05
- Resistance Level
- COCH $1.50
- OCX $2.24
- Average True Range (ATR)
- COCH 0.20
- OCX 0.21
- MACD
- COCH 0.01
- OCX -0.00
- Stochastic Oscillator
- COCH 32.26
- OCX 15.28
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.